百亿主动权益基金达20只！新星张璐夺冠！葛兰、谢治宇业绩反攻

Core Viewpoint - The market has shown signs of recovery, with the Shanghai Composite Index reaching 3600 points, leading to an expansion in the number of non-cash funds exceeding 10 billion yuan, with 226 such funds as of the end of Q2, representing approximately 0.98% of the total, an increase of 34 funds from Q1 [1][2]. Group 1: Fund Performance and Trends - As of the end of Q2, there are 20 active equity funds with over 10 billion yuan in assets, maintaining the same number as the end of Q1 [2]. - The total share of active equity funds in the market is 31.2 trillion shares, a decrease of 129.7 billion shares, or about 4%, compared to the end of last year [1]. - The average return of 8,302 active equity funds as of August 1 is 14.31%, outperforming the CSI 300 Index [1]. Group 2: Notable Fund Managers and Their Strategies - Zhang Lu from Yongying Fund has managed the "Yongying Advanced Manufacturing Smart Selection C" fund, which has seen a year-to-date return of 57.65% as of August 1, significantly higher than its benchmark [5][7]. - The fund's assets surged from 1.548 billion yuan at the end of 2024 to 10.869 billion yuan by the end of Q2 2023, indicating strong investor interest [5]. - The top five holdings of this fund are all related to the humanoid robot industry, reflecting a strategic focus on this emerging sector [5][6]. Group 3: Performance of Healthcare Funds - The "China Europe Medical Health A" and "China Europe Medical Health C" funds managed by Guo Lan have shown significant recovery, with year-to-date returns of 25.55% and 24.95%, respectively [8]. - The largest holding in these funds is WuXi AppTec, which constitutes 10.39% of the fund's net value, indicating a strong commitment to the healthcare sector [8][9]. Group 4: Insights from Fund Managers - Zhang Lu emphasizes the importance of production ramp-up in core robotics companies and government support for the robotics industry as key focus areas for Q3 [7]. - Guo Lan highlights the potential for domestic companies in the innovative drug sector to gain global recognition and the structural opportunities in the consumer healthcare sector due to rising health awareness [10]. - Xie Zhiyu from Xingsheng Global Fund points out that sectors like innovative drugs, smart driving, and new consumption are more suitable for value investors due to their solid performance backing [15].